Cardiovascular Disease

Using Extreme Genetics® & Opposite Phenotypes to identify new CVD targets.

Cardiovascular disease (CVD) is the number one cause of morbidity and mortality in the western world. With our partner Merck, we’re engaged in target validation studies using our clinical genetics platform of extreme and opposite phenotypes relevant to CVD and we are engaged in drug development of small molecule compounds targeting our genetically validated targets for the treatment of atherosclerosis. Merck executed its option to exclusively license the small molecule compounds developed for a novel cardiovascular disease target.